AMAG Pharmaceuticals, Inc. (AMAG) Receives “Hold” Rating from Cantor Fitzgerald

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued on Monday. They presently have a $23.00 target price on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 25.34% from the stock’s previous close.

The analysts wrote, “AMAG disclosed that the Makena auto-injector sNDA has been accepted for review and that the FDA set a PDUFA date of February 14, 2018.””

A number of other research analysts have also weighed in on the stock. Barclays PLC reissued an “equal weight” rating and set a $20.00 price target (down from $25.00) on shares of AMAG Pharmaceuticals in a research report on Thursday, June 1st. ValuEngine lowered shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. TheStreet lowered shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 5th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $34.00 price target (down from $40.00) on shares of AMAG Pharmaceuticals in a research report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the stock. AMAG Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $29.44.

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded down 1.36% during midday trading on Monday, hitting $18.10. 400,305 shares of the stock were exchanged. The stock’s market capitalization is $634.31 million. AMAG Pharmaceuticals has a 1-year low of $16.00 and a 1-year high of $36.83. The firm’s 50 day moving average is $18.26 and its 200-day moving average is $23.88.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by $1.15. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The business had revenue of $139.47 million for the quarter, compared to analyst estimates of $150.32 million. During the same quarter in the prior year, the business earned ($0.22) earnings per share. The firm’s quarterly revenue was up 27.6% compared to the same quarter last year. On average, analysts predict that AMAG Pharmaceuticals will post $5.09 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://transcriptdaily.com/2017/06/26/amag-pharmaceuticals-inc-amag-receives-hold-rating-from-cantor-fitzgerald.html.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $24.45, for a total value of $46,234.95. Following the sale, the senior vice president now owns 36,777 shares of the company’s stock, valued at $899,197.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Teachers Advisors LLC raised its stake in shares of AMAG Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 59,891 shares of the specialty pharmaceutical company’s stock valued at $2,084,000 after buying an additional 5,216 shares in the last quarter. Norges Bank bought a new stake in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $19,914,000. Thrivent Financial for Lutherans raised its stake in shares of AMAG Pharmaceuticals by 5.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 18,380 shares of the specialty pharmaceutical company’s stock valued at $640,000 after buying an additional 1,000 shares in the last quarter. Guggenheim Capital LLC raised its stake in shares of AMAG Pharmaceuticals by 46.5% in the fourth quarter. Guggenheim Capital LLC now owns 126,556 shares of the specialty pharmaceutical company’s stock valued at $4,404,000 after buying an additional 40,149 shares in the last quarter. Finally, Seven Eight Capital LP bought a new stake in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $212,000.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply